Minocycline Base

Hovione’s inhalation grade Glycopyrronium bromide (also known as Glycopyrrolate) particles are highly stable when exposed to high relative humidity and have zero amorphous content.

This highly crystalline micronized and stable Glycopyrrolate can only achieved thanks to Hovione’s extensive in...

Hovione has over 57 years of experience in the manufacture of corticosteroids with uncompromising quality and an unblemished Regulatory track record. ROUTE OF ADMINISTRATION: Topical   
REGULATORY STATUS: US DMF

CorticosteroidsROUTE OF ADMINISTRATION: Topical
REGULATORY STATUS: ASMF & VMF

Indacaterol for development trials with customized Particle Design, resulting in Inhalation grade material with highly customizable PSD to befit your application.
Our technology and expertise range yields unmatched impurity profiles with highly reproducibility between batches, resulting in a s...

The peace of mind of supply of a stable supplier, founding member of Rx-360 consortium. Hovione Ivermectin has high quality and we offer full regulatory support for human applications

ROUTE OF ADMINISTRATION: Oral, Topical

REGULATORY STATUS: CEP, US DMF, VMF
...

ROUTE OF ADMINISTRATION: Injectable

REGULATORY STATUS: DEV, TECH PACK

ROUTE OF ADMINISTRATION: Oral, Injectable, Topical 
REGULATORY STATUS: CEP, US DMF, JP DMF 

High performance APIs for inhalation as well as other demanding applications.  The diversity and experience in particle size reduction technologies provides our Customers with tailored made, highly reproducible particle size distributions. Low amorphous content and high stability w...

Proven expertise in development of high performance APIs for demanding applications such as inhalation or nasal suspensions. The range of particle size reduction technologies enables the manufacture of tailor made material with high particle size distribution reproducibility across batches a...

LABA/LAMAROUTE OF ADMINISTRATION: Inhalation
REGULATORY STATUS: DEV

ROUTE OF ADMINISTRATION: Oral, Injectable

REGULATORY STATUS: DEV

ROUTE OF ADMINISTRATION: Injectable

REGULATORY STATUS: DEV, TECH PACK

The new 31,000-sq. ft building will bring additional commercial spray drying capacity for customers who favour US-based manufacturing

Hovione announced today the appointment of Dr. Jean-Luc Herbeaux as Chief Operating Officer (COO), effective May 1st, 2020.

Hovione announced the signing of a partnership agreement with Ligand to significantly ramp up the production output of Captisol®

Ventofor Combi Fix delivered by the PowdAir Plus dry powder inhaler.